UK to offer new Covid-19 vaccine shots to Novavax trial volunteers

Around 15,000 people in the UK got Novavax shots as part of a clinical trial. While the UK recognizes them as vaccinated, most countries don't, meaning they can't travel

Novovax vaccine
FILE - This Wednesday, Oct. 7, 2020 file photo shows a vial of the Phase 3 Novavax coronavirus vaccine ready for use in a trial at St. George's University hospital in London. (Photo: AP)
AP London
2 min read Last Updated : Oct 08 2021 | 7:39 PM IST

Britain announced Friday that it will offer new vaccinations to thousands of people who volunteered for trials of the Novavax coronavirus vaccine, which hasn't yet been approved for use in any country.

Around 15,000 people in the UK got Novavax shots as part of a clinical trial. While the UK recognises them as vaccinated, most countries don't, meaning they can't travel.

Britain's health department said more than 15,000 participants will be given two doses of the Pfizer/BioNTech vaccine. The government says it plans to expand the offer to about 6,000 UK participants in trials of other vaccines that also haven't been approved for use.

Britain has appealed to other members of the Group of 20 nations to classify clinical trial volunteers as vaccinated, but most haven't done so.

England's deputy chief medical officer, Jonathan Van-Tam, noted that if more countries around the world had reciprocated by allowing UK volunteers to enjoy fully vaccinated status for overseas travel, these measures would not have been necessary.

In June, Novavax announced that its vaccine had proved about 90% effective against symptomatic COVID-19 in a study of nearly 30,000 people in the US and Mexico.

US-based Novavax has asked the World Health Organisation to approve its COVID-19 vaccine for emergency use so it can be part of the COVAX global vaccine programme. But it has delayed seeking approval in Europe or the United States.

The Novavax shots are easier to store and transport than some other options, and have long been expected to play an important role in increasing supplies in poor countries desperate for more vaccine doses.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineUKclinical trials

First Published: Oct 08 2021 | 7:38 PM IST

Next Story